Recent announcements

Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
2021
September
Press Release
15 Sep
2021

Convergent Therapeutics and Point Biopharma Announce a Collaboration to Evaluate CONV 01-α (Rosopatamab-225Ac) in combination with PNT2002 for Progressive mCRPC

Phase I/II investigator-Initiated Trial to be conducted at Weill Cornell Medicine, led by Principal Investigator, Dr. Scott T. Tagawa

2021
September
Press Release
8 Sep
2021

NorthStar Medical Radioisotopes and POINT Biopharma Announce Supply Agreement for Therapeutic Medical Radioisotope Actinium-225

Northstar Medical Radioisotopes and POINT Biopharma today announced the signing of a supply agreement for the therapeutic medical radioisotope actinium-225 (Ac-225).

2021
September
Press Release
7 Sep
2021

POINT Biopharma to Present at the H.C. Wainwright 23rd Annual Global Investment Conference

POINT Biopharma today announced that the Company’s Chief Executive Officer, Dr. Joe McCann will present at the H.C. Wainwright 23rd Annual Global Investment Conference, being held from September 13-15, 2021.

2021
August
Press Release
13 Aug
2021

POINT Biopharma Reports Second Quarter 2021 Financial Results and Provides Business Update

POINT Biopharma Global Inc. (NASDAQ: PNT) (the “Company” or “POINT”), a company accelerating the discovery, development and global access to life changing radiopharmaceuticals, today announced financial results for the second quarter...

2021
August
Press Release
10 Aug
2021

POINT Biopharma Announces Early Completion of Enrollment and Initial Dosing in the Lead-In of its Phase 3 SPLASH study of PNT2002 for mCRPC

Announcing the completion of enrollment and initial dosing of the 25-patient safety and dosimetry lead-in of the Company’s Phase 3 SPLASH study evaluating PNT2002 for the treatment of metastatic castration-resistant prostate cancer

2021
July
Press Release
21 Jul
2021

POINT Biopharma and Isotopia Announce Lutetium-177 Clinical Supply Agreement

Isotopia to supply POINT with no-carrier-added Lu-177 for use in POINT’s Indianapolis, IN radioligand production facility

2021
June
Press Release
30 Jun
2021

POINT Biopharma Debuts as Publicly Traded Next-Generation Radiotherapeutics Company

Common stock to commence trading on the Nasdaq Capital Market on July 1, 2021 under the ticker symbol “PNT”. Gross proceeds from the transaction totaled approximately $286.7 million.

2021
June
Press Release
28 Jun
2021

POINT Biopharma Strengthens Senior Management Team with Appointment of Dr. Myra Rosario Herrle as EVP, Regulatory Affairs

POINT announced today the appointment of Myra Herrle, Ph.D., R.Ph., RAC as Executive Vice President of Regulatory Affairs. Dr. Herrle brings over 27 years of experience in the pharmaceutical industry in areas such as regulatory affairs ...